Research Article|Articles in Press

Malignant salivary gland tumours: treatment outcomes from a tertiary referral centre in the UK


      Salivary gland malignant tumours are a complex and highly variable pathological group. Their diagnosis can be challenging, and management guided by multi-disciplinary teams. This project aimed to establish clinicopathological and sociodemographic features that significantly impacted overall disease-free or progression-free survival in patients diagnosed with malignant salivary gland disease between 2010 – 2019 in a tertiary referral centre.
      A total of 86 patients were included for analysis, with a gender ratio of F:M 1.3:1. Mean age at diagnosis was 57.7 years. Mucoepidermoid carcinomas constituted almost 25% (n=20) of all cases, with adenoid cystic carcinomas (20%, n = 17) and acinic cell carcinomas (17.5%, n = 15) being the next most frequently diagnosed. The parotid gland was the most frequently affected site (80.2%, n = 69).
      Perineural and lymphovascular invasion, maximum tumour dimension ≥4 cm were highly associated with the decision to provide a neck dissection as part of treatment efforts. Involved margins, extracapsular spread, lymphovascular and perineural invasion were associated with need for adjuvant treatment. However, there were no factors that remained statistically significant on multivariate analysis.
      This retrospective service evaluation demonstrates the difficulty of predicting treatment outcomes for patients diagnosed with malignant salivary gland disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. El-Naggar AK CJ, Grandis JR, Takata T, Slootweg PJ. WHO Classification of Head and Neck Tumours. 4th Edition. 2017.

      2. Ferrell JK, Mace JC and Clayburgh D. Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2019; 276: 1135-1146. 2019/01/17. DOI: 10.1007/s00405-019-05282-2.

        • Speight P.M.
        • Barrett A.W.
        Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification.
        Diagnostic Histopathology. 2020; 26: 147-158
      3. UK CR. Salivary gland cancer., (2022, accessed 25th May 2022).

      4. UK CR. Head and neck cancer statistics, (2021, accessed 15 September 2021 2021).

        • Seer
        SEER Explorer: An interactive website for SEER cancer statistics.
        Surveillance Research Program, National Cancer Institute. 2021; (accessed 26th May 2022)
      5. Jethwa AR and Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev 2017; 36: 411-423. 2017/08/13. DOI: 10.1007/s10555-017-9689-6.

      6. Praud D, Rota M, Rehm J, et al. Cancer incidence and mortality attributable to alcohol consumption. International journal of cancer 2016; 138: 1380-1387. 2015/10/13. DOI: 10.1002/ijc.29890.

      7. Sawabe M, Ito H, Takahara T, et al. Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. Cancer 2018; 124: 118-124. 2017/09/08. DOI: 10.1002/cncr.30957.

        • Li T.-I.
        • Chiang M.-T.
        • Chiu K.-C.
        • et al.
        The association of betel quid, alcohol, and cigarettes with salivary gland tumor—A case–control study.
        Journal of Dental Sciences. 2017; 12: 151-155
        • Orell sr.
        Diagnostic difficulties in the interpretation of fine needle aspirates of salivary gland lesions: the problem revisited.
        Cytopathology. 1995; 6: 285-300
      8. Howlett DC, Skelton E and Moody AB. Establishing an accurate diagnosis of a parotid lump: evaluation of the current biopsy methods - fine needle aspiration cytology, ultrasound-guided core biopsy, and intraoperative frozen section. The British journal of oral & maxillofacial surgery 2015; 53: 580-583. 2015/04/19. DOI: 10.1016/j.bjoms.2015.03.015.

      9. Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005; 61: 103-111. 2005/01/05. DOI: 10.1016/j.ijrobp.2004.03.018.

        • Speight P.
        • Barrett A.
        Salivary gland tumours.
        Oral Diseases. 2002; 8: 229-240
        • Yamada S.-i.
        • Kurita H.
        • Kamata T.
        • et al.
        Significant prognostic factors affecting treatment outcomes of salivary gland carcinoma: a multicenter retrospective analysis.
        Odontology. 2018; 106: 96-102
        • Terhaard C.H.J.
        Postoperative and Primary Radiotherapy for Salivary Gland Carcinomas: Indications, Techniques, and Results.
        International Journal of Radiation Oncology, Biology, Physics. 2007; 69: S52-S55
      10. Cohen RB, Delord JP, Doi T, et al. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. American journal of clinical oncology 2018; 41: 1083-1088. 2018/02/21. DOI: 10.1097/coc.0000000000000429.

        • Institute N.C.
        SEER Relative Survival by Cancer Site, 2001–2007.
        Cancer of the Oral Cavity and Pharynx. 2008;
        • Bakst R.L.
        • Su W.
        • Ozbek U.
        • et al.
        Adjuvant radiation for salivary gland malignancies is associated with improved survival: A National Cancer Database analysis.
        Advances in Radiation Oncology. 2017; 2: 159-166
        • Iwata A.J.
        • Williams A.M.
        • Taylor A.R.
        • et al.
        Socioeconomic disparities and comorbidities, not race, affect salivary gland malignancy survival outcomes.
        The Laryngoscope. 2017; 127: 2545-2550
      11. NHSA. Northern Head and Neck Alliance, (2022, accessed 30th November 2022).

      12. Sood S, McGurk M and Vaz F. Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. The Journal of laryngology and otology 2016; 130: S142-s149. 2016/11/15. DOI: 10.1017/s0022215116000566.

      13. Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head & neck 2016; 38: 620-627. 2014/12/10. DOI: 10.1002/hed.23925.

      14. Hancock BD. Clinically benign parotid tumours: local dissection as an alternative to superficial parotidectomy in selected cases. Ann R Coll Surg Engl 1999; 81: 299-301. 2000/01/25.

      15. Wilson TC and Robinson RA. Basal cell adenocarcinoma and Basal cell adenoma of the salivary glands: a clinicopathological review of seventy tumors with comparison of morphologic features and growth control indices. Head Neck Pathol 2015; 9: 205-213. 2014/08/22. DOI: 10.1007/s12105-014-0562-4.

      16. Gore MR. Epithelial-myoepithelial carcinoma: a population-based survival analysis. BMC Ear Nose Throat Disord 2018; 18: 15. 2018/08/22. DOI: 10.1186/s12901-018-0063-2.

      17. Patel EJ, Oliver JR, Liu C, et al. Outcomes of carcinoma ex pleomorphic adenoma compared to de novo adenocarcinoma of major salivary glands. J Surg Oncol 2021; 123: 446-455. 2020/11/05. DOI: 10.1002/jso.26289.

      18. van Weert S, Reinhard R, Bloemena E, et al. Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck. Head & neck 2017; 39: 456-463. 2016/10/25. DOI: 10.1002/hed.24613.

      19. Patel NR, Sanghvi S, Khan MN, et al. Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. The Laryngoscope 2014; 124: 172-178. 2013/06/12. DOI: 10.1002/lary.24231.

      20. Al-Mamgani A, van Rooij P, Verduijn GM, et al. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat Oncol Biol Phys 2012; 84: 189-195. 2012/02/15. DOI: 10.1016/j.ijrobp.2011.11.045.